FGF23 ELISA Kit (Fibroblast Growth Factor 23)

Full Name: FGF23 ELISA Kit (Fibroblast Growth Factor 23)
Reactivity: Human
Sample Type: Plasma, Tissue Homogenates, Serum, Biological Fluids
Sensitivity: 9.375 pg/ml

INTRODUCTION

Fibroblast growth factor 23 (FGF23) is a hormone produced by osteocytes regulating phosphate homeostasis and vitamin D metabolism. As a key regulator of mineral balance, FGF23 lowers circulating phosphate levels by downregulating renal phosphate reabsorption while also suppressing vitamin D activation to decrease intestinal absorption. Thereby it counterbalances elevations in serum phosphate preventing precipitation of calcium phosphate crystals compromising bone and kidney health. However, bone-kidney axis disruption arises in chronic kidney disease (CKD), wherein FGF23 dysregulation induces systemic toxicity.

FGF23 elicits downstream signaling by binding FGF receptors in complex with the cofactor α-Klotho expressed in key target tissues including kidneys, parathyroid glands and choroid plexus. Upon phosphate surplus sensed by bone osteocytes, FGF23 transcription and cleavage secretion increases. By diminishing expression of sodium-phosphate cotransporters NPT2a and NPT2c in proximal renal tubules, FGF23 prompts phosphaturia to lower circulating phosphate available to tissues. Concurrently, FGF-23 suppresses enzymes that activate vitamin D, resulting in reduced dietary phosphate absorption. Through this concerted bone-kidney crosstalk, FGF23 maintains phosphate within narrow physiologic ranges optimal for cellular bioenergetics.

However, as CKD progresses, diminishing kidney function compels markedly elevated FGF23 production attempting to offset disability in renal phosphate excretion. This FGF-23 overload drives pathological effects including cardiovascular disease and immune dysfunction when amplified over 100-fold. Elevated FGF23 later induces secondary hypoparathyroidism and Renal osteodystrophy. Furthermore, direct FGF23-mediated cardiomyoctye toxicity contributes to left ventricular hypertrophy and arrhythmias even prior to advanced CKD. Hence, mitigating excess FGF23 signaling has emerged as a promising therapeutic approach against disorders of bone-mineral metabolism and associated cardiovascular burden in CKD.

INTENDED USE

Human FGF23 ELISA kit can measure concentrations of fibroblast growth factor 23 (FGF23, HYPF, phosphatonin) present is plasma, serum, biological fluids or tissue homogenate samples.

CONTENT

All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.

One 96-Well Plate: Pre-coated with anti-FGF23 antibody.
Standards: Lyophilized recombinant.
Sample/Standard Dilution Buffer.
Biotinylated-labelled Antibody.
Antibody Dilution Buffer.
HRP-Streptavidin Conjugate (SABC).
SABC Dilution Buffer.
TMB Substrate.
Wash Buffer (25x).
Plate Sealer.
Product Instructions.

TYPICAL RESULTS

For this FGF23 ELISA kit, it is recommended that a standard curve is generated for each assay carried out.

Standard Curve: 0, 15.625, 31.25, 62.5, 125, 250, 50, 1000 pg/ml.
Reactivity: Human
Sensitivity: 9.375 pg/ml
Range: 15.625 – 1000 ng/ml
Principle: Sandwich, Double Antibody
Application: Research Use Only.

ASSAY CHARACTERISTICS

– Specificity: Highly specific for FGF23, no cross reactivity or interference between FGF23 and analogues was detected.
– Recovery: Serum (87 – 105%), EDTA Plasma (86 – 104%), Heparin Plasma (91 – 103%).
– Linearity: Serum (85 – 95%), EDTA Plasma (87 – 101%), Heparin Plasma (85 – 100%).
– Precison Intra-Assay: CV < 8%
– Precison Inter-Assay: CV < 10%

REFERENCES

FGF23 signalling and physiology. J Mol Endocrinol. (2021) 66 (2): R23-R32. Ho B.B. and Bergwitz C.
Fibroblast Growth Factor 23-Mediated Bone Disease. Endocrinol Metab Clin North Am. (2017) 46 (1): 19-39. Gonciulea A.R. and Jan De Beur S.M.
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol. (2021) 66 (2): R57-R65. Fukumoto S.
Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23). J Mol Med (Berl). (2021) 99 5): 699-711. Feger M., et al.

OTHER RELATED ELISA KITS

Online Enquiry Form

"*" indicates required fields